Pomerantz Probes Fraud at Multiple Tech, Biotech Firms

Pomerantz LLP has initiated investigations into potential securities fraud or misconduct at several publicly traded companies, now including Schrödinger, Luminar Technologies, Summit Therapeutics, Aurora Cannabis, and Meta Platforms. The investigations follow recent negative events such as executive departures at Schrödinger and Luminar (the latter after an internal code of conduct inquiry), poor clinical trial results at Summit, financial warnings at Aurora, and delays in Meta's AI model rollout. These incidents have triggered significant stock price declines, with drops ranging from nearly 3% for Meta to over 30% for Summit. Pomerantz LLP is urging affected investors to consider joining class action lawsuits. The firm is noted for its expertise in securities litigation and continues to represent shareholders impacted by corporate misconduct. The updates underscore continuing risks in both tech and biotech sectors.